Matches in SemOpenAlex for { <https://semopenalex.org/work/W4297266576> ?p ?o ?g. }
Showing items 1 to 56 of
56
with 100 items per page.
- W4297266576 endingPage "101822" @default.
- W4297266576 startingPage "101822" @default.
- W4297266576 abstract "Cuantificar, describir el origen y estimar el coste de las solicitudes de antígeno prostático específico (PSA) con fines de cribado a varones de 70 años o más realizadas en una zona de salud urbana.Estudio transversal. Se obtuvieron todas las determinaciones de PSA a pacientes adscritos a una zona de salud entre los años 2018 y 2020. Se clasificaron retrospectivamente como cribado (PSAc) o no, de acuerdo a criterios preestablecidos revisando historiales clínicos. Se comparó la edad de los pacientes sometidos a cribado con aquellos que no lo fueron. Se calcularon tasas de solicitud por centros y solicitantes de acuerdo a la población de referencia provista por el padrón municipal (VM70). Se estimó el coste consultando las tarifas de facturación.Fueron estudiadas 2.036 PSA, de 888 hombres ≥ 70 años, y 350 clasificadas como cribado. Se diagnosticaron seis adenocarcinomas. Se estimaron 76,07 PSAc/1.000 VM70-año con origen en cualquier centro, 1,45 solicitudes por individuo cribado, y una prevalencia de 15,71%; población media de referencia de 1.534 hombres (DE 45,37). Los pacientes sometidos a cribado (edad media 75 años, DE 4,04) fueron más jóvenes que aquellos no cribados (media 76,5, DE 4,81). Se estimó un coste del cribado de 9.751 €.Se describe la epidemiología y estima el coste de los cribados con PSA a varones ≥ 70 años sin cáncer prostático en nuestra zona, en atención primaria y hospitalaria. Se trata de una práctica habitual, predominantemente en atención primaria, y en magnitud similar a la reportada en la bibliografía estatal.To describe the epidemiology and estimate the cost of Prostate-Specific Antigen (PSA) screening tests to men ≥ 70 years old in an urban health zone.A cross-sectional study was performed. We obtained every PSA test made in the health zone from 2018 to 2020, and classified them retrospectively as screening (PSAc) or not according to pre-established criteria, reviewing electronic health records. Testing rates were calculated by centres and clinical specialities. The standard population was provided by the city register of inhabitants (VM70). Cost estimation was made using our health system's price list.Two thousand and thirty six PSA, of 888 men ≥ 70 years old were obtained, and 350 met screening classification criteria. Six adenocarcinomas were diagnosed from those tests. We estimated 76.07 PSAc/1000 VM70-year from any centre, 1.45 tests for each screened individual, and 15.71% prevalence. The standard population was 1534 men (mean 2018-2020, SD 45.37). Patients who were screened (median age 75, SD 4.04) were younger than those not screened. We estimated a total screening test cost of 9,751 €.The epidemiology and cost of PSA screening tests to men ≥ 70 years old are reported, both in primary health care and in the hospital. PSA screening tests are common practice amongst professionals attending elderly men in our health zone, mostly in primary care. The screening testing rate of men without prostate cancer is similar to that reported in the literature." @default.
- W4297266576 created "2022-09-28" @default.
- W4297266576 creator A5014507623 @default.
- W4297266576 creator A5024651399 @default.
- W4297266576 creator A5028722952 @default.
- W4297266576 creator A5056285534 @default.
- W4297266576 creator A5074580335 @default.
- W4297266576 date "2023-01-01" @default.
- W4297266576 modified "2023-10-17" @default.
- W4297266576 title "Adenopatías retroauriculares y escara necrótica en cuero cabelludo, una combinación sospechosa" @default.
- W4297266576 cites W1497087342 @default.
- W4297266576 cites W2260038148 @default.
- W4297266576 cites W2344599923 @default.
- W4297266576 cites W2426301794 @default.
- W4297266576 cites W2748985040 @default.
- W4297266576 cites W2912161249 @default.
- W4297266576 cites W3022299267 @default.
- W4297266576 cites W4225275808 @default.
- W4297266576 doi "https://doi.org/10.1016/j.semerg.2022.101822" @default.
- W4297266576 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36155263" @default.
- W4297266576 hasPublicationYear "2023" @default.
- W4297266576 type Work @default.
- W4297266576 citedByCount "0" @default.
- W4297266576 crossrefType "journal-article" @default.
- W4297266576 hasAuthorship W4297266576A5014507623 @default.
- W4297266576 hasAuthorship W4297266576A5024651399 @default.
- W4297266576 hasAuthorship W4297266576A5028722952 @default.
- W4297266576 hasAuthorship W4297266576A5056285534 @default.
- W4297266576 hasAuthorship W4297266576A5074580335 @default.
- W4297266576 hasConcept C142362112 @default.
- W4297266576 hasConcept C15708023 @default.
- W4297266576 hasConcept C71924100 @default.
- W4297266576 hasConceptScore W4297266576C142362112 @default.
- W4297266576 hasConceptScore W4297266576C15708023 @default.
- W4297266576 hasConceptScore W4297266576C71924100 @default.
- W4297266576 hasIssue "1" @default.
- W4297266576 hasLocation W42972665761 @default.
- W4297266576 hasLocation W42972665762 @default.
- W4297266576 hasOpenAccess W4297266576 @default.
- W4297266576 hasPrimaryLocation W42972665761 @default.
- W4297266576 hasRelatedWork W1506200166 @default.
- W4297266576 hasRelatedWork W1995515455 @default.
- W4297266576 hasRelatedWork W2048182022 @default.
- W4297266576 hasRelatedWork W2080531066 @default.
- W4297266576 hasRelatedWork W2604872355 @default.
- W4297266576 hasRelatedWork W2748952813 @default.
- W4297266576 hasRelatedWork W2899084033 @default.
- W4297266576 hasRelatedWork W3031052312 @default.
- W4297266576 hasRelatedWork W3032375762 @default.
- W4297266576 hasRelatedWork W3108674512 @default.
- W4297266576 hasVolume "49" @default.
- W4297266576 isParatext "false" @default.
- W4297266576 isRetracted "false" @default.
- W4297266576 workType "article" @default.